Capivasertib information

Capivasertib
Clinical data
Trade names	Truqap
Other names	AZD-5363, AZD5363
AHFS/Drugs.com	Truqap
MedlinePlus	a623056
License data	US DailyMed: Capivasertib;
Pregnancy; category	AU: D; ;
Routes of; administration	By mouth
Drug class	Threonine kinase inhibitor
ATC code	L01EX27 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only;
Identifiers
	IUPAC name 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide;
CAS Number	1143532-39-1;
PubChem CID	25227436;
DrugBank	DB12218;
ChemSpider	28189073;
UNII	WFR23M21IE;
KEGG	D11371;
ChEBI	CHEBI:229222;
ChEMBL	ChEMBL2325741;
PDB ligand	0XZ (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID40150710 ;
ECHA InfoCard	100.208.066
Chemical and physical data
Formula	C21H25ClN6O2
Molar mass	428.92 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES NC1(CCN(CC1)C1=C2C=CNC2=NC=N1)C(=O)N[C@@H](CCO)C1=CC=C(Cl)C=C1;
	InChI InChI=1S/C21H25ClN6O2/c22-15-3-1-14(2-4-15)17(6-12-29)27-20(30)21(23)7-10-28(11-8-21)19-16-5-9-24-18(16)25-13-26-19/h1-5,9,13,17,29H,6-8,10-12,23H2,(H,27,30)(H,24,25,26)/t17-/m0/s1; Key:JDUBGYFRJFOXQC-KRWDZBQOSA-N;

Capivasertib, sold under the brand name Truqap, is an anti-cancer medication used for the treatment of breast cancer.^[3]^[4] It is taken by mouth.^[3]

The most common adverse reactions include diarrhea, cutaneous adverse reactions, increased random glucose, decreased lymphocytes, decreased hemoglobin, increased fasting glucose, nausea, fatigue, decreased leukocytes, increased triglycerides, decreased neutrophils, increased creatinine, vomiting, and stomatitis.^[5]

In November 2023, capivasertib was approved in the United States for people with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer when used in combination with fulvestrant.^[5]^[6]^[7] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.^[8]

^ "Truqap (AstraZeneca Pty Ltd)". Therapeutic Goods Administration (TGA). 31 May 2024. Retrieved 17 June 2024.
^ "Notice: Multiple Additions to the Prescription Drug List (PDL) [2024-04-30]". Health Canada. 30 April 2024. Retrieved 3 May 2024.
^ ^a ^b ^c "Truqap- capivasertib tablet, film coated". DailyMed. 16 November 2023. Archived from the original on 20 November 2023. Retrieved 20 November 2023.
^ Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, et al. (June 2023). "Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer". New England Journal of Medicine. 388 (22): 2058–2070. doi:10.1056/NEJMoa2214131. PMID 37256976. S2CID 259002400.
^ ^a ^b "FDA approves capivasertib with fulvestrant for breast cancer". U.S. Food and Drug Administration. 16 November 2023. Archived from the original on 17 November 2023. Retrieved 17 November 2023. This article incorporates text from this source, which is in the public domain.
^ "Oncology (Cancer) / Hematologic Malignancies Approval Notifications". U.S. Food and Drug Administration. 16 November 2023. Archived from the original on 17 November 2023. Retrieved 17 November 2023.
^ "Truqap (capivasertib) plus Faslodex approved in the US for patients with advanced HR-positive breast cancer". AstraZeneca (Press release). 17 November 2023. Archived from the original on 17 November 2023. Retrieved 17 November 2023.
^ New Drug Therapy Approvals 2023 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2024. Archived from the original on 10 January 2024. Retrieved 9 January 2024.

[1] "Truqap (AstraZeneca Pty Ltd)". Therapeutic Goods Administration (TGA). 31 May 2024. Retrieved 17 June 2024.

[2] "Notice: Multiple Additions to the Prescription Drug List (PDL) [2024-04-30]". Health Canada. 30 April 2024. Retrieved 3 May 2024.

[Truqap_FDA_label-3] "Truqap- capivasertib tablet, film coated". DailyMed. 16 November 2023. Archived from the original on 20 November 2023. Retrieved 20 November 2023.

[4] Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, et al. (June 2023). "Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer". New England Journal of Medicine. 388 (22): 2058–2070. doi:10.1056/NEJMoa2214131. PMID 37256976. S2CID 259002400.

[FDA_Truqap-5] "FDA approves capivasertib with fulvestrant for breast cancer". U.S. Food and Drug Administration. 16 November 2023. Archived from the original on 17 November 2023. Retrieved 17 November 2023. This article incorporates text from this source, which is in the public domain.

[6] "Oncology (Cancer) / Hematologic Malignancies Approval Notifications". U.S. Food and Drug Administration. 16 November 2023. Archived from the original on 17 November 2023. Retrieved 17 November 2023.

[7] "Truqap (capivasertib) plus Faslodex approved in the US for patients with advanced HR-positive breast cancer". AstraZeneca (Press release). 17 November 2023. Archived from the original on 17 November 2023. Retrieved 17 November 2023.

[New_Drug_Therapy_Approvals_2023-8] New Drug Therapy Approvals 2023 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2024. Archived from the original on 10 January 2024. Retrieved 9 January 2024.

Capivasertib information

and 3 Related for: Capivasertib information

Capivasertib

Breast cancer

ATC code L01